

Resource Summary Report

Generated by [NIF](#) on Sep 10, 2026

CLB-Ga

RRID:CVCL_9529

Type: Cell Line

Proper Citation

RRID:CVCL_9529

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_9529

Proper Citation: RRID:CVCL_9529

Description: Cell line CLB-Ga is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Neuroblastoma

Defining Citation: [PMID:7705946](#), [PMID:11550280](#), [PMID:18534018](#), [PMID:18923523](#), [PMID:20160348](#)

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: CLB-Ga

Synonyms: CLB-GA, CLB-GAR

Cross References: cancercellines:CVCL_9529, Cosmic:1153805, Cosmic:1526623, Wikidata:Q54813559

ID: CVCL_9529

Record Creation Time: 20220427T215508+0000

Record Last Update: 20260905T174619+0000

Ratings and Alerts

No rating or validation information has been found for CLB-Ga.

No alerts have been found for CLB-Ga.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Gautier M, et al. (2026) A regulatory circuitry driving a noradrenergic to mesenchymal transition highlights YAP/TAZ as critical players in neuroblastoma plasticity. Cell reports, 45(5), 117351.

Hollander JF, et al. (2025) Serially Quantifying TERT Rearrangement Breakpoints in ctDNA Enables Minimal Residual Disease Monitoring in Patients with Neuroblastoma. Cancer research communications, 5(1), 167.

Montuori G, et al. (2025) Extrachromosomal DNA-Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers. Cancer discovery, 15(10), 2054.

Bobin C, et al. (2024) Sequential Analysis of cfDNA Reveals Clonal Evolution in Patients with Neuroblastoma Receiving ALK-Targeted Therapy. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(15), 3316.

Arlt B, et al. (2021) Inhibiting phosphoglycerate dehydrogenase counteracts chemotherapeutic efficacy against MYCN-amplified neuroblastoma. International journal of cancer, 148(5), 1219.

Chen J, et al. (2021) Targeted Therapy of TERT-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(5), 1438.